Evidence map›Paper›PMID 38275323›Full record

ArticleAntibiotics (Basel, Switzerland)2023

Competition between H

Ji-Fang Yu, Jin-Tian Xu, Ao Feng, Bao-Ling Qi, Jing Gu, Jiao-Yu Deng, Xian-En Zhang

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The T120P or M172V mutation onEmerging microbes & infections · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ji-Fang YuFaculty of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.ORCID 0000-0003-2446-6975
Jin-Tian XuWuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China.ORCID 0000-0001-9847-1617
Ao FengWuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China.
Bao-Ling QiShanghai Metabolome Institute-Wuhan (SMI), Wuhan 430000, China.
Jing GuWuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China.
Jiao-Yu DengWuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China.
Xian-En ZhangFaculty of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Chinese Academy of Sciences · CN

Funding

the National Key Research and Development Program of China 2021YFA1300901the Strategic Priority Research Program of the Chinese Academy of Sciences XDB29020000
6 · The paper itself

Abstract

Tuberculosis remains a serious challenge to human health worldwide.

Indexed as

Mycobacterium tuberculosispara-aminosalicylic acidtetrahydrofolatethyA

Identifiers

PMID38275323
PMCPMC10812664
OpenAlexW4390052158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.